secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001193125-23-250357
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology reports positive interim Phase 2 ASPEN-06 data for evorpacept in HER2+ gastric cancer
--------------------------------------------------------------------------------

- Confirmed ORR 52% for evorpacept combo vs 22% control; median DOR not reached vs 7.4 months.
- First positive randomized data for any CD47 blocker in solid tumors; safety consistent with prior trials.
- Phase 3 ASPEN-06 initiation planned late 2024; final Phase 2 results expected Q2 2024.
- Stratification factors (2nd/3rd line, prior ENHERTU) prespecified and balanced per protocol.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312523250357/0001193125-23-250357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312523250357/d539238d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-250357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer